Solventum (NYSE:SOLV) versus Femasys (NASDAQ:FEMY) Head-To-Head Survey

Solventum (NYSE:SOLV) and Femasys (NASDAQ:FEMY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Solventum and Femasys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Femasys	-534.36%	-225.97%	-74.68%

Insider and Institutional Ownership

65.3% of Femasys shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 7.7% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Solventum has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.07, suggesting that its share price is 307% less volatile than the S&P 500.

Valuation & Earnings

This table compares Solventum and Femasys”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.32 billion	1.79	$1.56 billion	$8.18	10.69
Femasys	$2.29 million	10.17	-$18.63 million	($3.53)	-0.79

Solventum has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Solventum and Femasys, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1	3	8	0	2.58
Femasys	1	0	3	0	2.50

Solventum presently has a consensus target price of $92.80, suggesting a potential upside of 6.15%. Femasys has a consensus target price of $50.00, suggesting a potential upside of 1,698.56%. Given Femasys’ higher probable upside, analysts clearly believe Femasys is more favorable than Solventum.

Summary

Solventum beats Femasys on 10 of the 14 factors compared between the two stocks.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.